DEA Reschedules Cannabis: What You Need to Know

In a milestone move, the Drug Enforcement Administration is calling for cannabis to be reclassified under federal law, according to an AP report. For the first time, the DEA has indicated that "botanical cannabis" should be reclassified, marking a significant shift in federal drug policy.

Cannabis stocks surged on Tuesday following news of the DEA's potential reclassification. The federal government's plan would move marijuana from its current classification as a Schedule I drug, which is considered highly dangerous and addictive with no medical use, to a lower scheduling that would allow for medical prescriptions.

According to CNN, the Biden administration is taking steps to reclassify marijuana as a less risky substance. This decision by the DEA is seen as a monumental shift in drug policy that could have far-reaching implications.

The DEA's move to reschedule cannabis as a Schedule III drug is imminent, as reported by The Washington Post. This decision has been met with a mix of reactions, with some praising the change and others expressing criticism.

Officials from a leading marijuana prohibitionist advocacy group have acknowledged that the DEA's decision to reschedule marijuana is generating a range of responses. The implications of this decision are still being assessed, but it is clear that this move will have a significant impact on the cannabis industry.

Overall, the DEA's decision to reclassify cannabis marks a major shift in federal drug policy. This move could pave the way for greater acceptance and regulation of marijuana at the federal level, opening up new opportunities for research and medical use.